Apomorphine intranasal - Nastech Pharmaceutical Company

Drug Profile

Apomorphine intranasal - Nastech Pharmaceutical Company

Latest Information Update: 14 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nastech Pharmaceutical Company
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Erectile dysfunction; Female sexual dysfunction

Most Recent Events

  • 14 Aug 2006 No development reported - Phase-II for Erectile dysfunction in USA (Intranasal)
  • 14 Aug 2006 No development reported - Phase-II for Female sexual dysfunction in USA (Intranasal)
  • 28 Apr 2004 Nastech has completed the phase II Maximum Tolerated Dose trial in Erectile dysfunction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top